ECOG E2100 A Randomized Phase III Trial of Paclitaxel vs Paclitaxel and Bevacizumab as First Line Therapy For Locally Recurrent or Metastatic Breast Cancer.

Trial Profile

ECOG E2100 A Randomized Phase III Trial of Paclitaxel vs Paclitaxel and Bevacizumab as First Line Therapy For Locally Recurrent or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Mar 2012 Actual patient number number changed from 789 to 722 as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Actual end date changed from Jan 2008 to May 2009 as reported by ClinicalTrials.gov.
    • 17 Dec 2010 Tolerability results presented in a Genentech media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top